SANDPIPER: Phase III study of the PI3-kinase (PI3K)...

Annals of Oncology 2016 / 10 Vol. 27; Iss. suppl_6

SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours

Baselga, J., Cortes Castan, J., De Laurentiis, M., Dieras, V., Harbeck, N., Hsu, J., Jin, H., Schimmoller, F., Wilson, T.R., Im, Y-H., Jacot, W., Krop, I.E., Verma, S.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw365.92
Date:
October, 2016
File:
PDF, 46 KB
english, 2016
Conversion to is in progress
Conversion to is failed